Addition of plerixafor in poorly mobilized allogeneic stem cell donors
Authors:
Open Access
- 28 May 2022
- journal article
- research article
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 37 (4) , 388-394
Abstract
Background: Peripheral blood stem cells (PBSCs) are the predominant graft source for adult allogeneic hematopoietic stem cell transplantation (HSCT). In poorly mobilized autologous donors, plerixafor improves collection outcomes. We examine plerixafor use in allogeneic donors who mobilize poorly with granulocyte colony‐stimulating factor (G‐CSF) in those who are healthy and those with pre‐existing medical conditions, and determine the optimal threshold to add plerixafor.Study Design/Methods: We retrospectively examined all allogeneic PBSC collections from January 2013 to October 2020 at our center. Donors received G‐CSF 10 mcg/kg daily for 4 days before undergoing apheresis collection on day 5. Plerixafor was added based on poor CD34+ cell collection yield after the first or second collection day.Results: Of the 1008 allogeneic donors, 41 (4.1%) received one dose of plerixafor in addition to G‐CSF due to poor collection yield. After starting plerixafor there was a 0.75‐ to 7.74‐fold (median 2.94) increase in CD34+ yield from the previous day. No donors with G‐CSF‐only mobilization who collected 6 CD34+ cells/kg recipient weight on day one achieved the goal of ≥4.0 × 106 CD34+ cells/kg recipient weight total over 2 days but 59.2% of donors who used rescue plerixafor did.Conclusion: Donors both healthy and those with pre‐existing disease responded well to plerixafor with minimal side effects. If the first‐day collection yield is less than ~63% of the collection goal, addition of plerixafor may be necessary to reach the collection goal and limit the number of collection days in allogeneic donors.Keywords
This publication has 36 references indexed in Scilit:
- Novel agents and approaches for stem cell mobilization in normal donors and patientsBone Marrow Transplantation, 2011
- Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patientsBone Marrow Transplantation, 2010
- Plerixafor ‘just in time’ for stem cell mobilization in a normal donorBone Marrow Transplantation, 2010
- Successful mobilization of PBSCs in a healthy volunteer donor by addition of plerixafor after failure of mobilization with G-CSF aloneBone Marrow Transplantation, 2010
- FDA Review Summary: Mozobil in Combination with Granulocyte Colony-Stimulating Factor to Mobilize Hematopoietic Stem Cells to the Peripheral Blood for Collection and Subsequent Autologous TransplantationOncology, 2010
- AMD3100 for urgent PBSC mobilization and allogeneic transplantation from a normal donor after failed marrow harvestBone Marrow Transplantation, 2010
- Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interactionBlood, 2008
- Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony‐stimulating factor (G‐CSF): impact of age, sex, donor weight and type of G‐CSF usedBritish Journal of Haematology, 2006
- Evaluation of Hematopoietic Stem Cell DonorsHematology-American Society Hematology Education Program, 2005
- Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonistBlood, 2003